In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene

International Journal of Antimicrobial Agents

Volumn 44, Issue 1, 2014, Pages 65-68

  Arhin, Francis F ^a   Sarmiento, Ingrid ^a   Moeck, Gregory ^a  

^a Medicines Company   (Canada)

Author keywords

mecC; MRSA; Oritavancin

Indexed keywords

DAPTOMYCIN; LINEZOLID; ORITAVANCIN; PENICILLIN BINDING PROTEIN 2A; VANCOMYCIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; GLYCOPEPTIDE; OXAZOLIDINONE DERIVATIVE;

ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BIOASSAY; BROTH DILUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE AMPLIFICATION; GROWTH REGULATION; IN VITRO STUDY; MECA GENE; MECC GENE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SKIN AND SKIN STRUCTURE INFECTION; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS ATCC 29213; STAPHYLOCOCCUS AUREUS ATCC 33591; STAPHYLOCOCCUS AUREUS ATCC 43300; TIME KILL ASSAY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; PENICILLIN RESISTANCE;

ACETAMIDES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DAPTOMYCIN; GENE EXPRESSION; GLYCOPEPTIDES; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; OXAZOLIDINONES; VANCOMYCIN;

EID: 84902546245     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.03.015     Document Type: Article

References (15)

1. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement, document M100-S24 2014 CLSI Wayne, PA
2. L. García-Álvarez, M.T. Holden, H. Lindsay, C.R. Webb, D.F. Brown, and M.D. Curran et al. Meticillin-resistant Staphylococcus aureus with a novel mecA homologue in human and bovine populations in the UK and Denmark: a descriptive study Lancet Infect Dis 11 2011 595 603
3. T. Ito, K. Hiramatsu, A. Tomasz, H. de Lencastre, V. Perreten, and M.T. Holden et al. Guidelines for reporting novel mecA gene homologues Antimicrob Agents Chemother 56 2012 4997 4999
4. A. Petersen, M. Stegger, O. Heltberg, J. Christensen, A. Zeuthen, and L.K. Knudsen et al. Epidemiology of methicillin-resistant Staphylococcus aureus carrying the novel mecC gene in Denmark corroborates a zoonotic reservoir with transmission to humans Clin Microbiol Infect 19 2013 E16 E22
5. G.K. Paterson, E.M. Harrison, and M.A. Holmes The emergence of mecC methicillin-resistant Staphylococcus aureus Trends Microbiol 22 2014 42 47
6. LGA251 J Antimicrob Chemother 67 2012 2238 2241
7. LGA251 Clin Microbiol Infect 18 2012 395 400
8. G.G. Zhanel, F. Schweizer, and J.A. Karlowsky Oritavancin: mechanism of action Clin Infect Dis 54 2012 S214 S219
9. Corey R., Perez A., Moeck G., Jiang H., Good S., and SOLO I Investigators A single-dose of oritavancin (ORI) is comparable to 7-10 days of vancomycin (VAN) in the treatment of acute bacterial skin and skin structure infections (ABSSSI): the SOLO I study 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 10-13 September 2013, Denver, CO 2013 ASM Press Washington, DC [abstract L-204]
10. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, document M7-A9 9th ed. 2012 CLSI Wayne, PA
11. F.F. Arhin, A. Belley, G.A. McKay, S. Beaulieu, I. Sarmiento, and T.R. Parr Jr. et al. Assessment of oritavancin serum protein binding across species Antimicrob Agents Chemother 54 2010 3481 3483
12. A. Belley, F.F. Arhin, I. Sarmiento, H. Deng, W. Rose, and G. Moeck Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant Staphylococcus aureus infection Antimicrob Agents Chemother 57 2013 205 211
13. National Committee for Clinical and Laboratory Standards Methods for determining bactericidal activity of antimicrobial agents; approved guideline, document M26-A 1999 NCCLS Wayne, PA
14. R.E. Mendes, D.J. Farrell, H.S. Sader, and R.N. Jones Oritavancin microbiologic features and activity results from the surveillance program in the United States Clin Infect Dis 54 2012 S203 S213
15. G.A. McKay, S. Beaulieu, F.F. Arhin, A. Belley, I. Sarmiento, and T. Parr Jr. et al. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium J Antimicrob Chemother 63 2009 1191 1199